AbbVie Enters Obesity Market with Positive ABBV-295 Phase 1 Results

AbbVie has reported positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment. The trial showed meaningful, dose-dependent reductions in body weight, setting it apart from widely discussed GLP-1 and GIP agonists. This marks AbbVie's entry into the competitive anti-obesity drug market and supports its aim to diversify beyond immunology. The non-incretin mechanism of action adds another angle to AbbVie's pipeline story and could be a key factor to watch in future trial stages.